Lista de obras - Marco Rossi - Dominio Público Uruguay

A comparative effectiveness study of lipegfilgrastim in multiple myeloma patients after high dose melphalan and autologous stem cell transplant

scientific article published on 18 December 2019

A comprehensive safety evaluation of trabectedin and drug-drug interactions of trabectedin-based combinations.

artículo científico publicado en 2014

A peroxisome proliferator-activated receptor gamma (PPARG) polymorphism is associated with zoledronic acid-related osteonecrosis of the jaw in multiple myeloma patients: analysis by DMET microarray profiling.

artículo científico publicado en 2011

A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells.

artículo científico publicado en 2011

Anti-tumor Activity and Epigenetic Impact of the Polyphenol Oleacein in Multiple Myeloma

scientific article published on 16 July 2019

Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma

artículo científico publicado en 2012

Dendritic cells have the option to express IDO-mediated suppression or not

artículo científico publicado en 2005

Enumeration of interleukin-10-positive B cells from peripheral blood of patients with chronic lymphocytic leukemia

artículo científico publicado en 2014

Evidence of shared epitopic reactivity among independent B-cell clones in chronic lymphocytic leukemia patients.

artículo científico publicado en 2016

From target therapy to miRNA therapeutics of human multiple myeloma: theoretical and technological issues in the evolving scenario.

artículo científico

Immunologic microenvironment and personalized treatment in multiple myeloma.

artículo científico publicado en 2013

In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells.

artículo científico publicado en 2014

In vivo anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor.

artículo científico publicado en 2008

Indoleamine 2,3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells.

scientific article published on 22 May 2009

Inhibition of miR-21 restores RANKL/OPG ratio in multiple myeloma-derived bone marrow stromal cells and impairs the resorbing activity of mature osteoclasts

artículo científico publicado en 2015

Intestinal toxicity during induction chemotherapy with cytarabine-based regimens in adult acute myeloid leukemia

artículo científico publicado en 2003

MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells

artículo científico publicado en 2017

Mir-221/222 are promising targets for innovative anticancer therapy.

artículo científico publicado en 2016

Molecular targets for the treatment of multiple myeloma.

artículo científico

Mouse models of multiple myeloma: technologic platforms and perspectives.

artículo científico publicado en 2018

Network meta-analysis of randomized trials in multiple myeloma: efficacy and safety in relapsed/refractory patients

artículo científico publicado en 2017

Non-Coding RNAs in Multiple Myeloma Bone Disease Pathophysiology

scientific article published on 09 September 2020

Peptide-loaded Langerhans cells, despite increased IL15 secretion and T-cell activation in vitro, elicit antitumor T-cell responses comparable to peptide-loaded monocyte-derived dendritic cells in vivo.

artículo científico publicado en 2011

Plasmacytoid dendritic cells: do they have a role in immune responses after hematopoietic cell transplantation?

artículo científico publicado en 2002

Promises and Challenges of MicroRNA-based Treatment of Multiple Myeloma ⬇️

artículo científico publicado el 1 de septiembre de 2012

Quality of life outcomes in multiple myeloma patients: a summary of recent clinical trials

scientific article published on 03 July 2019

Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma

artículo científico publicado en 2019

Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomised trials

artículo científico publicado en 2012

Role of nucleophosmin in embryonic development and tumorigenesis

scientific journal article

Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo.

artículo científico publicado en 2015

Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence.

artículo científico publicado en 2012

Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth

artículo científico publicado en 2013

The Non-Coding RNA Landscape of Plasma Cell Dyscrasias

scientific article published on 30 January 2020

Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92

scientific article published on 11 July 2018

Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma

scientific article published on 21 March 2019

Whole-body MRI and PET/CT in multiple myeloma patients during staging and after treatment: personal experience in a longitudinal study ⬇️

artículo científico publicado el 26 de junio de 2013

miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myeloma

artículo científico publicado en 2020

miR-22 suppresses DNA ligase III addiction in multiple myeloma

artículo científico publicado en 2018

miR-29b induces SOCS-1 expression by promoter demethylation and negatively regulates migration of multiple myeloma and endothelial cells

artículo científico publicado en 2013

miR-29b negatively regulates human osteoclastic cell differentiation and function: implications for the treatment of multiple myeloma-related bone disease

artículo científico publicado en 2013

miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1

artículo científico publicado en 2012

Lista de obras de Marco Rossi

A comparative effectiveness study of lipegfilgrastim in multiple myeloma patients after high dose melphalan and autologous stem cell transplant

A comprehensive safety evaluation of trabectedin and drug-drug interactions of trabectedin-based combinations.

A peroxisome proliferator-activated receptor gamma (PPARG) polymorphism is associated with zoledronic acid-related osteonecrosis of the jaw in multiple myeloma patients: analysis by DMET microarray profiling.

A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells.

Anti-tumor Activity and Epigenetic Impact of the Polyphenol Oleacein in Multiple Myeloma

Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma

Dendritic cells have the option to express IDO-mediated suppression or not

Enumeration of interleukin-10-positive B cells from peripheral blood of patients with chronic lymphocytic leukemia

Evidence of shared epitopic reactivity among independent B-cell clones in chronic lymphocytic leukemia patients.

From target therapy to miRNA therapeutics of human multiple myeloma: theoretical and technological issues in the evolving scenario.

Immunologic microenvironment and personalized treatment in multiple myeloma.

In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells.

In vivo anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor.

Indoleamine 2,3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells.

Inhibition of miR-21 restores RANKL/OPG ratio in multiple myeloma-derived bone marrow stromal cells and impairs the resorbing activity of mature osteoclasts

Intestinal toxicity during induction chemotherapy with cytarabine-based regimens in adult acute myeloid leukemia

MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells

Mir-221/222 are promising targets for innovative anticancer therapy.

Molecular targets for the treatment of multiple myeloma.

Mouse models of multiple myeloma: technologic platforms and perspectives.

Network meta-analysis of randomized trials in multiple myeloma: efficacy and safety in relapsed/refractory patients

Non-Coding RNAs in Multiple Myeloma Bone Disease Pathophysiology

Peptide-loaded Langerhans cells, despite increased IL15 secretion and T-cell activation in vitro, elicit antitumor T-cell responses comparable to peptide-loaded monocyte-derived dendritic cells in vivo.

Plasmacytoid dendritic cells: do they have a role in immune responses after hematopoietic cell transplantation?

Promises and Challenges of MicroRNA-based Treatment of Multiple Myeloma ⬇️

Quality of life outcomes in multiple myeloma patients: a summary of recent clinical trials

Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma

Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomised trials

Role of nucleophosmin in embryonic development and tumorigenesis

Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo.

Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence.

Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth

The Non-Coding RNA Landscape of Plasma Cell Dyscrasias

Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92

Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma

Whole-body MRI and PET/CT in multiple myeloma patients during staging and after treatment: personal experience in a longitudinal study ⬇️

miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myeloma

miR-22 suppresses DNA ligase III addiction in multiple myeloma

miR-29b induces SOCS-1 expression by promoter demethylation and negatively regulates migration of multiple myeloma and endothelial cells

miR-29b negatively regulates human osteoclastic cell differentiation and function: implications for the treatment of multiple myeloma-related bone disease

miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1